These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 17671123)

  • 1. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C; Agerbaek M; Von Der Maase H
    Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
    Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
    Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
    Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
    Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.
    Hussain SA; Ganesan R; Hiller L; Cooke PW; Murray P; Young LS; James ND
    Oncol Rep; 2003; 10(3):571-6. PubMed ID: 12684626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical significance of CD147 in genitourinary carcinomas.
    Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
    J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.
    Ju XZ; Yang JM; Zhou XY; Li ZT; Wu XH
    Clin Cancer Res; 2008 Jan; 14(2):494-501. PubMed ID: 18223224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
    Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
    BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
    Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
    Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
    Afonso J; Longatto-Filho A; Baltazar F; Sousa N; Costa FE; Morais A; Amaro T; Lopes C; Santos LL
    Eur J Surg Oncol; 2011 Sep; 37(9):811-7. PubMed ID: 21733655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.